{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:19:36Z","timestamp":1792091976294,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005382","name":"National Yang-Ming University in Taiwan","doi-asserted-by":"publisher","award":["107F-M01-07M32"],"award-info":[{"award-number":["107F-M01-07M32"]}],"id":[{"id":"10.13039\/501100005382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.bcp.2019.02.028","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:02:59Z","timestamp":1551178979000},"page":"308-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein"],"prefix":"10.1016","volume":"163","author":[{"given":"Hsin-Chia","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Cheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hung","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Oswita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Lien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ling","family":"Syu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuen-Miin","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsiung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-225X","authenticated-orcid":false,"given":"Shu-Ling","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9976","key":"10.1016\/j.bcp.2019.02.028_b0005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.02.028_b0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov. Today Technol."},{"issue":"21","key":"10.1016\/j.bcp.2019.02.028_b0015","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1158\/1078-0432.CCR-13-0258","article-title":"Ponatinib-a step forward in overcoming resistance in chronic myeloid leukemia","volume":"19","author":"Frankfurt","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.02.028_b0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nature Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2019.02.028_b0025","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1440-1681.2011.05633.x","article-title":"Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer","volume":"39","author":"Lim","year":"2012","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"8","key":"10.1016\/j.bcp.2019.02.028_b0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2174\/1568026616666160927150452","article-title":"Multi-targeting Andrographolide and its Natural Analogs as Potential Therapeutic Agents","volume":"17","author":"Kishore","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2019.02.028_b0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-009-1180-5","article-title":"Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial","volume":"28","author":"Burgos","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2019.02.028_b0040","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/846740","article-title":"Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide","volume":"2013","author":"Jayakumar","year":"2013","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.bcp.2019.02.028_b0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fpls.2015.00655","article-title":"Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials","volume":"6","author":"Jantan","year":"2015","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.bcp.2019.02.028_b0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2018.01.074","article-title":"Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer","volume":"420","author":"Islam","year":"2018","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bcp.2019.02.028_b0055","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/carcin\/bgt005","article-title":"The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer","volume":"34","author":"Lai","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2019.02.028_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.taap.2016.09.009","article-title":"Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt\/mTOR pathway","volume":"310","author":"Mi","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.02.028_b0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1615\/JEnvironPatholToxicolOncol.v30.i1.40","article-title":"Andrographolide inhibits human umbilical vein endothelial cell invasion and migration by regulating MMP-2 and MMP-9 during angiogenesis","volume":"30","author":"Pratheeshkumar","year":"2011","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2019.02.028_b0070","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3892\/mmr.2014.2872","article-title":"Inhibition of MDA-MB-231 breast cancer cell migration and invasion activity by andrographolide via suppression of nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression","volume":"11","author":"Zhai","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2019.02.028_b0075","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/13543776.2014.956084","article-title":"Andrographolide: progression in its modifications and applications - a patent review (2012\u20132014)","volume":"24","author":"Aromdee","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.bcp.2019.02.028_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152770","article-title":"Development of a Bifunctional Andrographolide-Based Chemical Probe for Pharmacological Study","volume":"11","author":"Hsu","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.bcp.2019.02.028_b0085","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1074\/jbc.M705877200","article-title":"Suppression of v-Src transformation by andrographolide via degradation of the v-Src protein and attenuation of the Erk signaling pathway","volume":"283","author":"Liang","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2019.02.028_b0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bcp.2013.10.014","article-title":"Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy","volume":"87","author":"Liu","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.02.028_b0095","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","article-title":"Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"290","author":"Lu","year":"2010","journal-title":"Cancer Lett."},{"issue":"15","key":"10.1016\/j.bcp.2019.02.028_b0100","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.bcp.2019.02.028_b0105","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.bcp.2019.02.028_b0110","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1055\/s-0030-1250039","article-title":"Andrographolide exhibits anti-invasive activity against colon cancer cells via inhibition of MMP2 activity","volume":"76","author":"Chao","year":"2010","journal-title":"Planta Med."},{"key":"10.1016\/j.bcp.2019.02.028_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key418","article-title":"Deltex1 suppresses T cell function and is a biomarker for diagnosis and disease activity of systemic lupus erythematosus","author":"Leu","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.bcp.2019.02.028_b0120","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bcp.2019.02.028_b0125","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3892\/ijo.2015.2960","article-title":"A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells","volume":"46","author":"Long","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"42","key":"10.1016\/j.bcp.2019.02.028_b0130","doi-asserted-by":"crossref","first-page":"44061","DOI":"10.18632\/oncotarget.6392","article-title":"ASXL1 mutation correction by CRISPR\/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts","volume":"6","author":"Valletta","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2019.02.028_b0135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jep.2006.10.026","article-title":"Protective activity of andrographolide and arabinogalactan proteins from Andrographis paniculata Nees. against ethanol-induced toxicity in mice","volume":"111","author":"Singha","year":"2007","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.02.028_b0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pmic.201200273","article-title":"A novel andrographolide derivative AL-1 exerts its cytotoxicity on K562 cells through a ROS-dependent mechanism","volume":"13","author":"Zhu","year":"2013","journal-title":"Proteomics"},{"issue":"1\u20133","key":"10.1016\/j.bcp.2019.02.028_b0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2007.04.027","article-title":"Andrographolide induces cell cycle arrest at G2\/M phase and cell death in HepG2 cells via alteration of reactive oxygen species","volume":"568","author":"Li","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.02.028_b0150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.bcp.2019.02.028_b0155","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back","volume":"17","author":"von Bubnoff","year":"2003","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.bcp.2019.02.028_b0160","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bcp.2019.02.028_b0165","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bcp.2019.02.028_b0170","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"Targeting HSP90 for cancer therapy","volume":"100","author":"Mahalingam","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2019.02.028_b0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1947601911409744","article-title":"Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer","volume":"2","author":"Liu","year":"2011","journal-title":"Genes Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219300668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219300668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:07:33Z","timestamp":1757768853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219300668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":35,"alternative-id":["S0006295219300668"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.02.028","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}